16 results about "Lung squamous cell carcinoma" patented technology

The invention discloses a lung cancer high-risk group screening questionnaire cognitive calculation correction method and system. The method comprises the following steps: acquiring questionnaire text data of a subject; constructing a BERT-QA model based on the clinical term knowledge graph, analyzing questionnaire text semantics, and extracting structured risk factor data; mapping the risk factor data to a topological space, and constructing a risk topological representation; calculating a dynamic weight coefficient of each risk factor based on an information entropy principle, and generating a risk assessment value of entropy weight optimization; carrying out calibration in combination with regional pollution map data; according to the method, deep learning, topology and fuzzy logic technologies are fused, intelligent analysis of questionnaire texts and dynamic weight calculation of risk factors are realized, environmental pollution factors are effectively integrated, the screening accuracy and individuation level are improved, and the method is suitable for large-scale popularization and application. The method provides technical support for accurate identification and early intervention of lung cancer high-risk groups, and has important clinical application value.

The application discloses radix sophorae tonkinensis polysaccharide STGP-1, a preparation method thereof and pharmaceutical use for treating lung squamous carcinoma, and relates to the technical field of medicines. The monosaccharide composition of STGP-1 includes fucose Fuc, arabinose Ara, galactose Gal, glucose Glc, xylose Xyl and mannose Man, and the molar ratio is 0.34:12.15:25.76:57.07:1.06:3.62. The STGP-1 is obtained by extraction, separation and purification from dried roots and rhizomes of radix sophorae tonkinensis, and the preparation method comprises the steps of pretreatment and crude extraction, impurity removal treatment, anion exchange column chromatography separation, gel column chromatography purification and the like. The STGP-1 can be used alone or in combination with anti-PD-1 monoclonal antibody for preparing a medicine for treating lung squamous carcinoma. The preparation process is stable, the source is natural, and the STGP-1 can provide a new high-efficiency and low-toxicity candidate medicine for immune combined treatment of lung squamous carcinoma.

The invention provides a lung squamous cell carcinoma organoid culture medium and a culture method. The lung squamous cell carcinoma organoid culture medium is prepared from the following components: R-spondin-1, Noggin, EGF (Epidermal Growth Factor), FGF10 (Fibroblast Growth Factor), FGF7 (Fibroblast Growth Factor), A83-01, Y-27632, Nicotinamide, Insulin, B27 Supplement, N-Acetylcysteine, Alpisib, GlutaMAX, primary cell antibiotics and the like. The lung squamous cell carcinoma organoid culture medium can be used for efficiently culturing lung squamous cell carcinoma tissues and successfully obtaining organoid, the formed organoid is highly similar to primary lung squamous cell carcinoma tissues in cell type, polarity and spatial hierarchical structure, and the micropathologic characteristics of tumors are truly reproduced. And the organoid can be stably passaged for a long time, so that an ideal and reliable preclinical model is provided for pathogenesis research, personalized drug screening and novel therapy development of lung squamous cell carcinoma.

The invention relates to the technical field of biological medicine, and particularly discloses a lipidosome targeting SELENOP + macrophages, a preparation method of the lipidosome and application of the lipidosome in lung squamous cell carcinoma treatment. According to the lipidosome, an SELENOP antibody is used as a targeted modification molecule, si-SELENOP and s-ABCA1 / G1 are loaded, and accurate delivery of siRNA in target cells is achieved through specific binding of the antibody and a SELENOP receptor on the surface of a SELENOP + macrophage. The targeting liposome prepared by the invention can specifically inhibit cholesterol efflux pathways of SELENOP + macrophages, reverse tumor phenotypic polarization, remodel a tumor immune microenvironment and recover anti-tumor activity of immune cells such as CD8 + T cells, NK cells and the like. When the liposome is independently used or combined with a PD-1 antibody, the growth and metastasis of the lung squamous cell carcinoma can be remarkably inhibited, the treatment effect is improved, a brand new metabolism-immunity synergistic targeted treatment strategy is provided for the lung squamous cell carcinoma, and the liposome has a good clinical application prospect.

This invention provides the use of CX6258 or its salts in medicaments for the prevention and / or treatment of lung cancer, belonging to the field of biomedicine. This invention is the first to discover that CX6258HCl can effectively inhibit the growth of lung squamous cell carcinoma cell lines and organoids, and that CX6258HCl can also be combined with cisplatin to treat lung squamous cell carcinoma. Therefore, CX6258 or its salts have broad application prospects in medicaments for the prevention and / or treatment of lung cancer, especially lung squamous cell carcinoma.

The invention belongs to the technical field of molecular markers, and particularly relates to application of FGFBP2 as a lung squamous cell carcinoma diagnosis marker. The invention provides a biomarker for lung squamous cell carcinoma diagnosis, the biomarker is FGFBP2 gene or FGFBP2 protein, the content of the marker in serum of a lung squamous cell carcinoma patient is remarkably increased, the expression level of the marker in lung squamous cell carcinoma tissue is remarkably higher than that of a normal person, and the difference has statistical significance. By detecting the expression level of FGFBP2 in human serum, lung squamous cell carcinoma patients and normal people can be effectively distinguished, and the FGFBP2 can be used for diagnosing lung squamous cell carcinoma.

The application discloses application of a pathogenic transposable element pL1HS as a lung squamous carcinoma biomarker and a therapeutic target. The 5'-UTR region of the pathogenic transposable element pL1HS has a nucleic acid sequence as shown in SEQ ID NO. 1, and specific detection primers are shown in SEQ ID NO. 2 and SEQ ID NO. 3 respectively. Animal experiments prove that the combined application of the reverse transcription transposition inhibitor nevirapine and the cGAS inhibitor can significantly inhibit the growth of lung squamous carcinoma. The pathogenic transposable element pL1HS can be used as a novel molecular marker in the diagnostic application dimension, and provides a precise detection index for early screening, pathological typing and prognosis judgment of lung squamous carcinoma. In the treatment application dimension, the target intervention strategy for pL1HS, especially the combined medication scheme of multi-pathway inhibitors, opens up a new direction.

The invention provides a CA-4 piperazine derivative as well as a preparation method and application thereof, and relates to the field of chemical medicines. The structural formula of the CA-4 piperazine derivative is as shown in formula (1), when R1 is F, R2 is OCH3, and R3 is one of F, Cl, Br, CH3 and OCH3; when R1 is H, R2 is OCH3 or SCH3, and R3 is one of F, Cl, Br, CH3 and OCH3. According to the invention, the Combretastatin A-4 (CA-4) derivative is synthesized and prepared, compounds 32-46 are 15 new compounds, and research finds that the compounds 32-46 have an obvious inhibition effect on 4 tumor cells, and can be applied to preparation of vascular targeting preparation medicines for treating colorectal cancer, lung adenocarcinoma, gastric cancer and lung squamous carcinoma.

This invention relates to the pharmaceutical applications of MRPS7 as a diagnostic biomarker for non-small cell lung cancer (NSCLC) and its inhibitors, belonging to the field of biomedical technology. For the first time, this invention utilizes immunohistochemical analysis of tumor tissues from NSCLC patients and paired adjacent normal tissues to confirm that MRPS7 protein is significantly overexpressed in NSCLC tissues (p<0.001), and this difference is statistically significant in both lung adenocarcinoma and lung squamous cell carcinoma subtypes. Furthermore, this invention demonstrates through in vitro functional experiments that knocking down MRPS7 gene expression using siRNA targeting MRPS7 significantly inhibits the proliferation, migration, and invasion abilities of NSCLC cells (A549, SK-MES-1) (p<0.001). Therefore, reagents for detecting MRPS7 expression levels can be used to prepare NSCLC diagnostic products, and MRPS7 inhibitors can be used to prepare drugs for treating NSCLC. This invention provides a novel molecular biomarker for the diagnosis of NSCLC and a new strategy for targeted therapy of NSCLC.

The invention relates to the technical field of cell biology and biological medicine, and particularly discloses a co-culture system construction method based on TGM2 targeted regulation of mesenchymal stem cells and a co-culture system prepared by the method. The method comprises the following steps: respectively preparing human umbilical cord mesenchymal stem cells, lung adenocarcinoma cells A549 and lung squamous carcinoma cells SW1573 in a logarithmic phase; mixing A549 and SW1573 cells according to a ratio of 1: 1 to obtain mixed lung cancer cells; and mixing the hUC-MSC and the mixed lung cancer cells according to a quantitative ratio of 5: 1 to 13: 1, inoculating the mixture into a culture container containing a culture medium, and culturing for 3-9 days under the conditions of 37 DEG C and 5% CO2 to obtain the co-culture system. The method does not need to carry out gene modification on hUC-MSC, and can effectively inhibit proliferation, migration and invasion of lung cancer cells and induce the lung cancer cells to generate cell cycle arrest and apoptosis by optimizing the co-culture proportion and time and utilizing natural communication between cells.

The invention belongs to the technical field of gene engineering, and particularly relates to a recombinant plasmid for inhibiting PLANE gene expression, a preparation method of the recombinant plasmid and a recombinant adeno-associated virus, and the recombinant plasmid comprises a nucleotide sequence for encoding shRNA of a targeted PLANE gene. The scAAV5.PLANE.shRNA recombinant plasmid carrying the shRNA sequence of the targeted PLANE gene is creatively constructed, the recombinant virus with infection activity is successfully packaged, in-vivo experiments prove that the recombinant virus can remarkably inhibit in-vivo growth of lung squamous carcinoma cells, and compared with other virus vectors, the recombinant virus has lower immunogenicity and higher biological safety, and can be used for preparing the lung squamous carcinoma cells. And a new choice is provided for clinical gene therapy.

The invention discloses application of liensinine perchlorate in preparation of a medicine for treating lung cancer, and the liensinine perchlorate is used for preparing the medicine for treating the lung cancer or used for preparing a sensitizing medicine for immunotherapy of the lung cancer, and the lung cancer comprises large-cell lung cancer, small-cell lung cancer, lung adenocarcinoma or lung squamous carcinoma. The liensinine perchlorate or the pharmaceutically acceptable solvate thereof is used as an active ingredient, and the prognosis of a patient is improved by inhibiting the growth of lung cancer cells and improving the immunotherapy curative effect of lung cancer, so that the survival rate of five years is improved. Cell experiments show that liensinine perchlorate inhibits the growth of lung cancer cells in a concentration gradient dependent manner, animal experiments show that liensinine perchlorate can significantly inhibit the growth of subcutaneous tumors, and the growth of lung cancer can be further inhibited in combination with PD-L1 monoclonal antibody treatment. In addition, liensinine perchlorate is easy to obtain, soluble in water, high in safety and capable of being directly taken orally, and a novel safe and effective method for lung cancer treatment and lung cancer immunotherapy sensitization is provided.

This invention provides a traditional Chinese medicine composition for treating squamous cell carcinoma of the lung, its preparation method, and its application, belonging to the field of traditional Chinese medicine technology. The traditional Chinese medicine composition for treating squamous cell carcinoma of the lung provided by this invention comprises the following raw materials in parts by weight: 20-30 parts of Ziziphus jujuba seed, 15-20 parts of ginseng, 10-15 parts of dried ginger, 15-30 parts of stir-fried Atractylodes macrocephala, 40-50 parts of Paeonia lactiflora, 20-30 parts of Rehmannia glutinosa, 15-20 parts of Trichosanthes kirilowii root, 40-50 parts of stir-fried Coix lacryma-jobi, 5-7 parts of honey-processed Ephedra sinica, 20-30 parts of Poria cocos, 5-10 parts of frankincense, 5-10 parts of myrrh, 10-20 parts of Alpinia oxyphylla, 20-30 parts of vinegar-processed tortoise shell, 20-30 parts of vinegar-processed turtle shell, 10-20 parts of Albizia julibrissin bark, and 9-12 parts of prepared licorice root. The aforementioned traditional Chinese medicine composition can effectively improve various clinical symptoms caused by squamous cell carcinoma of the lung, while inhibiting the growth and metastasis of the cancer cells, with significant effects and no side effects.

The application provides a lung squamous carcinoma organoid culture medium and a culture method, the lung squamous carcinoma organoid culture medium is composed of R-spondin-1, Noggin, EGF, FGF10, FGF7, A83-01, Y-27632, Nicotinamide, Insulin, B27 Supplement, N-Acetylcysteine, Alpelisib, GlutaMAX, primary cell antibiotic and the like. The lung squamous carcinoma organoid culture medium can efficiently culture lung squamous carcinoma tissues and successfully obtain organoids, the formed organoids are highly similar to primary lung squamous carcinoma tissues in cell type, polarity and spatial hierarchical structure, and truly reproduce the microscopic pathological characteristics of tumors. Moreover, the organoids can be stably subcultured for a long time, and provide an ideal and reliable preclinical model for the pathogenesis research, personalized drug screening and new therapy development of lung squamous carcinoma.

The application discloses a pharmaceutical use of linopteridin and a medicine containing the linopteridin. The use is that the linopteridin is applied to preparing a TBK1 inhibitor, and the TBK1 inhibitor combined with an anti-PD-1 antibody is applied to preparing a medicine for treating lung squamous carcinoma. The medicine is a TBK1 inhibitor containing the linopteridin, and a medicine composition containing the linopteridin and the anti-PD-1 antibody. The linopteridin can directly combine and inhibit the TBK1 kinase activity, and reduce the TBK1 phosphorylation level. The linopteridin combined with the anti-PD-1 antibody can significantly inhibit the lung squamous carcinoma tumor growth and has good safety. The aspect provides a new drug administration approach for treating the lung squamous carcinoma.